Nanotechnology Databases

Comprehensive databases for nanomaterials, events, products,
companies, research labs, degree programs and publications


Nanobiotechnology and Nanomedicine Companies


Showing results 26 - 50 of 73 for companies in category Delivery:

One of the company's delivery systems in the most advanced stages of clinical development is a novel drug delivery system for Paclitaxel. Because of the better safety and pharmacokinetic profile, the polymeric nanoparticle delivery system is seen as a potential super generic.
Applies nanotechnology to the design and manufacture of pumps, coatings and micro-needle arrays.
Delpor develops the next generation Drug Delivery Systems that improve the clinical and commercial value of drugs and biopharmaceuticals. The company also has developed a microfabricated nanopore device for the sustained release of therapeutic agents.
The company is focused on the use of fullerene carbon nanotubes for novel therapeutic applications specifically in the area of cancer treatment. The company's extensive carbon nanotube-related, worldwide intellectual property portfolio includes discoveries by the late Nobel Prize winner Dr Rick Smalley. The use of fullerene carbon nanotubes has the goal of solving two important problems for many cancer therapeutics, that of delivering large active agents into the desired location and of protecting normal tissue from the active agent during delivery.
The company develops unique molecular delivery systems. Its spherical micrometer sizes polymer particles act like micro sponges and absorb molecules while the sub-micrometer sized Hollow silica shells have an internal void space and act much like a standard container.
Manufactures Medusa®, a self-assembled poly-aminoacid nanoparticles system that is a versatile protein carrier for the development of novel and second-generation long-acting native protein drugs.
The company's targeted nanocapsule technology is designed using a flexible formulation process and can carry large or small molecules, custom target delivery to different organs, tissues and cells, and be applied several ways including topically, intravenously, or via devices or tablets.
The company is developing therapeutic immunotherapy by incorporating virus-specific immunogenic DNA into nanoparticles.
iCeutica has developed the Encapsulated Organic Nanoparticles (EON™) Platform to produce consistent nano-sized drug particles.
The company's SonoLysis program is focused on the development of two product candidates that involve the administration of proprietary MRX-801 micro- and nanobubbles and ultrasound with or without a thrombolytic drug to break up blood clots and restore blood flow to oxygen deprived tissues.
The foundation of the company's IVEC™ drug delivery platform is based on polymer micelle technology, spherical nanosized capsules formed by the assembly of block copolymers in water.
Develops a nanoparticle-based siRNA targeting the VEGF (Vascular Endothelial Growth Factor) pathwayas part of its RNA interference (RNAi) therapeutics for the treatment of human diseases.
Develops and markets a nanoparticle vector technology that combines DNA with the lipids DOTAP and cholesterol to create a synthetic gene delivery vehicle.
Keystone Nano has an exclusive license to Penn State patented technology that allows the creation of stable, non-toxic, 5 to 50 nm-composite particles that they call Molecular Dots (MDs). These Molecular Dots can encapsulate drugs and/or fluorescent molecules.
Develops novel polymeric, nano-delivery systems for delivery of water-insoluble and poorly bio-available drugs.
Leonardo is the exclusive provider of a proprietary multistage drug delivery platform initially targeting the treatment of cancer. The first stage consists of silicon nanoparticles that are rationally designed to circumvent the biological barriers between injection and the target site. The non-toxic silicon nanoparticles can carry a variety of second stage delivery vehicles.
The combination of a protected blood transporting nanocarrier system and a tumor specific activation technology makes LiPlasome Pharma very competitive in a commercially attractive and dynamic anticancer market, where drug delivery systems will gain increasing importance over the coming years.
Living Cell is developing cell-based products to treat life threatening human diseases. The company has developed proprietary nanobiocapsules which allow encapsulated pig insulin producing cells, DiabeCell, to be implanted without the use of toxic immune suppressive drugs.
Provides integrated systems for nanotechnology-based cancer therapy.
Makefield Therapeutics has licensed Intellectual Property covering a novel platform technology from Albert Einstein College of Medicine of Yeshiva University for the generation of powders comprised of hydrogel/glassy matrix (hybrid) nanoparticles that in a first application are delivering controlled and sustained therapeutic levels of gaseous nitric oxide
The company utilizes its proprietary nanotechnology platform to transform existing and experimental anti-cancer agents into new, patentable drugs with superior pharmaceutical properties.
Develops nanoparticle based in vivo delivery applications.
Dedicated to finding new treatments for cancer based on the combined application of nanotechnologies and biotechnologies.
Applies the manufacturing technology of ultrafine particles termed 'micellar nanoparticles' to use them as carriers for drugs, such as anticancer agents.
Nanocopoeia is a therapeutic particle engineering company providing nano-enabled particle design, services, and equipment to the pharmaceutical industry. Their patented ElectroNanospray™ (ENS) process is used to produce homogeneous nanoparticles in a unique one-step continuous process. They have the ability to engineer multicomponent particles. ENS is a non-destructive process operating at ambient temperature and pressure. The modular equipment design allows for easy entry at R&D scale moving to pilot and full scale production.
left arrowBack to Nanotechnology Links Directory